MAP3K8/TPL-2 Protein, Human (sf9, GST)

MAP3K8/TPL-2 is critical for LPS-induced, TLR4-mediated activation of MAPK/ERK, leading to TNF production by macrophages. It regulates T cell differentiation, IFNG expression, and host resistance to bacterial infections by negatively regulating type I interferon production. MAP3K8/TPL-2 Protein, Human (sf9, GST) is the recombinant human-derived MAP3K8/TPL-2 protein, expressed by Sf9 insect cells , with N-GST labeled tag.

MAP3K8/TPL-2 is crucial for lipopolysaccharide (LPS)-induced, TLR4-mediated activation of the MAPK/ERK pathway in macrophages, playing a pivotal role in the production of the pro-inflammatory cytokine TNF-alpha (TNF) during immune responses. It also participates in the regulation of T-helper cell differentiation and IFNG expression in T-cells, contributing to the modulation of host resistance against bacterial infections by negatively regulating type I interferon (IFN) production. Furthermore, MAP3K8/TPL-2 is involved in transducing signals from CD40 and TNFRSF1A, activating ERK in B-cells and macrophages, and potentially influencing immunoglobulin production. In adipocytes, it activates the MAPK/ERK pathway in response to IL1B and TNF, contributing to the induction of lipolysis in an IKBKB-dependent manner. Additionally, MAP3K8/TPL-2 may play a role in the transduction of TNF signals that activate JNK and NF-kappa-B in specific cell types. Its involvement in the cell cycle is evident, with isoform 1 exhibiting some transforming activity, albeit weaker than that of the activated oncogenic variant.

Human

Sf9 insect cells

N-GST

P41279 (M30-R397)

1326  [NCBI]

Partial

MENLYASEEPAVYEPSLMTMCQDSNQNDERSKSLLLSGQEVPWLSSVRYGTVEDLLAFANHISNTAKHFYGQRPQESGILLNMVITPQNGRYQIDSDVLLIPWKLTYRNIGSDFIPRGAFGKVYLAQDIKTKKRMACKLIPVDQFKPSDVEIQACFRHENIAELYGAVLWGETVHLFMEAGEGGSVLEKLESCGPMREFEIIWVTKHVLKGLDFLHSKKVIHHDIKPSNIVFMSTKAVLVDFGLSVQMTEDVYFPKDLRGTEIYMSPEVILCRGHSTKADIYSLGATLIHMQTGTPPWVKRYPRSAYPSYLYIIHKQAPPLEDIADDCSPGMRELIEASLERNPNHRPRAADLLKHEALNPPREDQPR

Approximately 68 kDa,based on SDS-PAGE under reducing conditions.

≥ 90%, as determined by reducing SDS-PAGE.

<1 EU/μg, determined by LAL method.